Abstract: The invention describes kit of parts of polypeptides comprising: a) a peptide comprising: a1) an MHC class II T cell epitope or a CD1 d-restricted NKT cell epitope, and a2) immediately adjacent to said epitope or separated by at most 7 amino acids from said epitope a [CST]-X(2)-C [SEQ ID NO:7] or C-X(2)-[CST] [SEQ ID NO:8] oxidoreductase motif sequence, and b) a poly-peptide comprising: b1) a therapeutic protein and b2) the epitope defined in a1), wherein the epitope sequence is a sequence which differs from the sequence of the protein of b1). The therapeutic protein, in combination with the peptide, is used to prevent an immune response against the therapeutic protein.

Abstract: The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG [SEQ ID NO: 26] and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.

Abstract: The invention relates to immunogenic peptides derived from Myelin Oligodendrocyte Glycoprotein (MOG) for use in the treatment of demyelinating disorders and to the generation of cytolytic CD4+ T cells or NKT cells against antigen presenting cells that present the wild-type MOG epitope sequence.

Abstract: The invention describes kit of parts of polypeptides comprising: a) a peptide comprising: a1) an MHC class II T cell epitope or a CD1 d-restricted NKT cell epitope, and a2) immediately adjacent to said epitope or separated by at most 7 amino acids from said epitope a [CST]-X(2)-C [SEQ ID NO:7] or C-X(2)-[CST] [SEQ ID NO:8] oxidoreductase motif sequence, and b) a polypeptide comprising: b1) a therapeutic protein and b2) the epitope defined in a1), wherein the epitope sequence is a sequence which differs from the sequence of the protein of b1). The therapeutic protein, in combination with the peptide, is used to prevent an immune response against the therapeutic protein.

Abstract: The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG [SEQ ID NO: 26] and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.

Abstract: The present invention relates to a pharmaceutical preparation (combination or pharmaceutical composition or kit-of-parts) comprising one or more dose units of a fumarate compound and an immunogenic or tolerogenic peptide comprising an oxidoreductase motif and an NKT cell epitope or an MHC class II T cell epitope of an (auto)antigen involved in fumarate related diseases or disorders. The present invention further relates to medical uses of this pharmaceutical preparation.

Abstract: The present invention relates to a method of predicting the response of of type 1 diabetes patients to the treatment with an immunogenic peptide comprising an MHCII T cell epitope of insulin and an oxidoreductase motif, said method comprising determining the MHC class II HLA haplotype of the patient.

Abstract: The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG [SEQ ID NO: 26] and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.

Abstract: The invention concerns a plant and a method for treating gas by chemical, physical or hybrid absorption of compounds for removal, comprising at least: a) a step of absorption by contacting a gas for treatment with a depleted solvent to give a treated gas and a rich solvent; b) a step of optional separation by medium-pressure flashing c) a step of heat exchange between a fraction of the cold rich solvent and the hot depleted solvent in a first heat exchanger d) a step of heat exchange between the complementary fraction of the cold rich solvent and a hot gaseous effluent in a second exchanger e) a step of optional separation by low-pressure flashing f) a step of regeneration of the rich solvent by heating in a reboiler g) a step of separation by low-pressure flashing h) a cooling of the depleted solvent.

Abstract: The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG [SEQ ID NO: 26] and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.

Abstract: The present invention relates an in vitro method for detecting class II restricted CD4+ T cells in a sample. Herein a sample is contacted with an isolated complex of an MHC class II molecule and a peptide. This peptide comprises an MHC class II restricted T cell epitope of an antigenic protein and immediately adjacent thereof, or separated by a linker of at most 7 amino acids a sequence with a [CST]-xx-C or C-xx-[CST] motif. CD4+ T cells are detected by measuring the binding of the complex with cells in the sample, wherein the binding of the complex to a cell is indicative for the presence of CD4+ T cells in the sample. The present invention further relates to an isolated complex of an MHC Class II molecule and a peptide comprising an MHC class II restricted T cell epitope of an antigenic protein and immediately adjacent thereof, or separated by a linker of at most 7 amino acids a sequence with a [CST]-xx-C or C-xx-[CST] motif.

Abstract: The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.

Abstract: The invention relates to isolated immunogenic peptides comprising a MHC class II T cell epitope, and immediately adjacent or separated from said epitope a H-X(0,2)-C-X(2)-[CST] or [CST]-X(2)-C-X(0,2)-H redox motif.

Abstract: The present invention relates to a gas-redirecting device presenting an upper plane and a plurality of gas-redirecting tubes comprising an inlet end and an outlet end. For each gas-redirecting tube, the orthogonal projections of the inlet end and the outlet end onto the upper plane have an over-lapping area of at most 50% of the total area of the upper plane covered by the orthogonal projections. Also provided is a liquid-gas contacting column comprising a gas-redirecting device, a floating support comprising a liquid-gas contacting column, at least two packed beds and a method for improving the efficiency of a liquid-gas contacting column which is based on redirecting the gas from a wetted zone of a lower packed bed to a wetted zone of the higher packed bed.

Abstract: The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.

Abstract: The application relates to methods for determining a parameter such as toxicity and pharmacokinetic behavior for a pharmaceutical compound against a disease or disorder. The test animals being used are non-human animals not suffering from or is not showing symptoms or signs of the disorder and which do not provoke an immune response against said pharmaceutical compound. These animals are obtainable by administration of a peptide comprising an oxidoreductase motif further comprising an NKT peptide epitope or an MHC class II T cell epitope of said pharmaceutical compound, wherein said motif and said epitope are separated by a linker of between 0 and 4 amino acids.

Abstract: The present invention relates an in vitro method for detecting class II restricted CD4+ T cells in a sample. Herein a sample is contacted with an isolated complex of an MHC class II molecule and a peptide. This peptide comprises an MHC class II restricted T cell epitope of an antigenic protein and immediately adjacent thereof, or separated by a linker of at most 7 amino acids a sequence with a [CST]-xx-C or C-xx-[CST] motif. CD4+ T cells are detected by measuring the binding of the complex with cells in the sample, wherein the binding of the complex to a cell is indicative for the presence of CD4+ T cells in the sample. The present invention further relates to an isolated complex of an MHC Class II molecule and a peptide comprising an MHC class II restricted T cell epitope of an antigenic protein and immediately adjacent thereof, or separated by a linker of at most 7 amino acids a sequence with a [CST]-xx-C or C-xx-[CST] motif.

Abstract: The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.

Abstract: The present invention relates to a column (CO) for the exchange of material and, if appropriate, heat between a gas and a liquid. The exchange column (CO) comprises at least one collector tray and a system for distributing liquid arranged between two packing beds (7), and means for recirculating the liquid (8). The means for recirculating the liquid (8) connect a zone situated below the packing bed (7) to a zone situated above the distributor tray.

Abstract: The present invention relates to a liquid-gas contacting unit comprising a column, at least a lower packed bed and a higher packed bed positioned higher than the lower packed bed inside the column, a gas-tight liquid collecting and redistributing device disposed between the lower and the higher packed bed inside the column and an external pipe outside the column, the external pipe comprising an inlet end, an outlet end and a peripheral wall between the inlet end and the outlet end; the inlet end being positioned between the lower pack bed and the gas-tight liquid collecting and redistributing device and the outlet end being positioned between the higher pack bed and the gas-tight liquid collecting and redistributing device. The present invention also relates to a method for improving the efficiency of a liquid-gas contacting unit.